Submitted for Publication: June 21, 2011; final revision received December 19, 2011; accepted December 23, 2011.
Author Contributions: Dr Holt takes responsibility for the integrity of the data and the accuracy of the data analysis, and all authors had full access to all the data in the study.
Financial Disclosure: During the last 5 years, Dr Goff has served as a consultant or advisor to GlaxoSmithKline, Merck, Bristol-Myers Squibb, Wyeth, Organon, Xytis, XenoPort, Proteus, Vanda, AstraZeneca, Forest Laboratories, Pfizer, Indevus Pharmaceuticals, H. Lundbeck, Ortho-McNeil-Janssen Pharmaceuticals, Schering-Plough, Eli Lilly, Takeda Pharmaceuticals, Biovail, Solvay, Hoffmann-La Roche, Cypress Pharmaceutical, Dainippon Sumitomo Pharma, Abbott Laboratories, Genentech, and Endo Pharmaceuticals. He also served on a data safety monitoring board for Otsuka and Wyeth, and he has received research funding from Cephalon, Pfizer, Janssen, Novartis, and GlaxoSmithKline.
Funding/Support: This study was supported by grant K23MH076054 from the National Institute of Mental Health and funding from the National Alliance for Research on Depression and Schizophrenia with the Sidney R. Baer Jr Foundation to Dr Holt.
Previous Presentations: This study was presented in part at the 2010 Society for Neuroscience Meeting; November 16, 2010; San Diego, California; and the 2010 Annual Meeting of the American College of Neuropsychopharmacology; December 6, 2010; Miami, Florida.
Additional Contributions: We are grateful for the advice of Douglas Greve, PhD, and Eric Macklin, PhD, on the imaging and statistical analyses, respectively.